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Francisella tularensis (Ft) is a highly infectious Gram-negative bacterium and the causative agent of the human disease
tularemia. Ft is designated a class A select agent by the Centers for Disease Control and Prevention. Human clinical
isolates of Ft produce lipid A of similar structure to Ft subspecies novicida (Fn), a pathogen of mice. We identified three
enzymes required for Fn lipid A carbohydrate modifications, specifically the presence of mannose (flmF1),
galactosamine (flmF2), or both carbohydrates (flmK). Mutants lacking either galactosamine (flmF2) or galactos-
amine/mannose (flmK) addition to their lipid A were attenuated in mice by both pulmonary and subcutaneous routes
of infection. In addition, aerosolization of the mutants (flmF2 and flmK) provided protection against challenge with
wild-type (WT) Fn, whereas subcutaneous administration of only the flmK mutant provided protection from challenge
with WT Fn. Furthermore, infection of an alveolar macrophage cell line by the flmK mutant induced higher levels of
tumor necrosis factor-a (TNF-a) and macrophage inhibitory protein-2 (MIP-2) when compared to infection with WT Fn.
Bone marrow–derived macrophages (BMMø) from Toll-like receptor 4 (TLR4) and TLR2/4 knockout mice infected with
the flmK mutant also produced significantly higher amounts of interleukin-6 (IL-6) and MIP-2 than BMMø infected with
WT Fn. However, production of IL-6 and MIP-2 was undetectable in BMMø from MyD88
 /  mice infected with either
strain. MyD88
 /  mice were also susceptible to flmK mutant infection. We hypothesize that the ability of the flmK
mutant to activate pro-inflammatory cytokine/chemokine production and innate immune responses mediated by the
MyD88 signaling pathway may be responsible for its attenuation, leading to the induction of protective immunity by
this mutant.
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Introduction
Francisella tularensis (Ft) is a Gram-negative intracellular
bacterium that causes the severe and often fatal disease
tularemia in humans. Infection can occur through skin
contact, insect bite, or inhalation of contaminated air. Ft is
classiﬁed as a category A bioterrorism agent due to its high
infectivity and mortality, transmission by an airborne route
of infection [1–3], and development as a bioweapon.
Francisella is categorized into numerous subspecies: tularensis
(Type A), holarctica (Type B), mediasiatica, and novicida. Ft Type
A and Type B cause disease in humans, with Type A being the
most virulent. Francisella novicida (Fn) causes a severe disease
in a murine model but is not virulent in immunocompetent
humans. Interestingly, all subspecies share greater than 95%
DNA sequence homology, suggesting a close genetic relation-
ship and allowing Fn to be considered an acceptable model
for studying Francisella LPS biosynthesis and pathogenicity
[1,4].
Lipid A, the biologically active component of Gram-
negative bacterial lipopolysaccharide (LPS), is responsible
for various pathological responses in Gram-negative bacterial
infections [5–7]. Classical biphosphorylated, hexa-acylated
lipid A species from Escherichia coli can activate pro-
inﬂammatory responses through Toll-like receptor 4
(TLR4), while tetra- or penta-acylated lipid A species have
signiﬁcantly diminished immunostimulatory activity [5,8].
The lipid A molecule can be modiﬁed by the addition of
various carbohydrates, removal of phosphate moieties, or
variation in the length and/or order of fatty acid chains,
altering recognition by the host innate immune system.
Francisella LPS and lipid A molecules lack immunostimulatory
activity and are not recognized by TLR2 or TLR4 [9,10] and
display little to no endotoxic properties in galactosamine-
treated mice, by limulus assay (a standard for determining
LPS endotoxin potential), after aerosolization in mice, or by
stimulation of mononuclear cells to release cytokines [11–13].
The b-(1,6)-linked diglucosamine backbone structure of
Francisella lipid A has amide-linked fatty acids at the 2 ((18:0)-
3-OH) and 29 positions and ester-linked fatty acids at the 3
((18:0)-3-OH), but not the 39 positions [14–17]. A fatty acid
(16:0) is attached to the 29 fatty acid, forming an acyloxyacyl
group ((18:0)-3-(16:0)). Francisella subspecies lipid A has a
single phosphate moiety at the 1 position of the reducing
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with the positively charged sugar galactosamine [15], which
was recently shown to be a-linked in Fn by Wang et al. [18]
(Figure 1B, m/z 1665). Finally, the 49 phosphate is absent and
can be removed by the recently identiﬁed phosphatase LpxF
[18].
In this study, we screened transposon-generated Fn
mutants for enzymes involved in lipid A biosynthesis and
modiﬁcation. Two proposed dolichyl phosphate-mannose
synthase-like enzymes, FlmF1 (FTN_1403) and FlmF2
(FTN_0545), required for the synthesis of the undecapren-
yl-phospho-mannose or galactosamine donor lipid, respec-
tively, and a proposed glycosyltransferase enzyme, FlmK
(FTN_0546), required for the addition of both mannose and
galactosamine to lipid A, were identiﬁed.
Fn mutants (ﬂmF2 and ﬂmK) were attenuated in mice after
subcutaneous and pulmonary infection and provided pro-
tection against a lethal wild-type (WT) Fn infection. In
addition, the ﬂmK mutant stimulated an increased innate
immune response as compared to WT Fn or other bacterial
lipid A biosynthetic mutants. This increased immune
activation appears to involve the MyD88 signaling pathway.
This study shows attenuation of virulence and the induction
of protective immunity in both subcutaneous and pulmonary
routes of infection by Fn mutants with altered lipid A.
Results
Enzymes Involved in Carbohydrate Modification of
Francisella Lipid A
In enteric bacteria, two enzymes are required for the
synthesis of the undecaprenyl-phospho-aminoarabinose do-
nor lipid (PmrF/ArnC) and addition (PmrK/ArnT) of amino-
arabinose to lipid A [19,20]. The genes encoding these
enzymes in Fn were determined using clusters of orthologous
groups (COG), gene ontology (GO), and/or PFAM database–
based searches for conserved motifs to the Salmonella
typhimurium enzymes. Twenty-three putative Fn orthologs of
the S. typhimurium PmrK and PmrF genes were identiﬁed.
Lipid A, derived from individual transposon mutants in the
Fn orthologs after growth at 37 8C using an ammonium
hydroxide/isobutyric acid extraction method, was subjected
to matrix-assisted laser desorption ionization time-of-ﬂight
(MALDI-TOF) mass spectrometry (MS) analysis in the
negative ion mode. Only three individual Fn mutants were
identiﬁed that showed altered lipid A carbohydrate mod-
iﬁcation, as compared to WT Fn (Figure 1).
Negative ion MALDI-TOF MS analysis of lipid A isolated
from the WT Fn strain (U112) after growth at 37 8C showed a
dominant peak at mass/charge (m/z) 1665 that corresponded
to a tetra-acylated base structure with a galactosamine
residue at the 1 position phosphate (Figure 1A). A minor
ion species at m/z 1504 corresponded to the loss of the
galactosamine modiﬁcation (-D161 m/z), whereas the ion
species at m/z 1827 represented the addition of a second
hexose residue (þD162 m/z). Finally, the ion peak at m/z 1637
consisted of lipid A structures with smaller acyl chains
compared to m/z 1665 and was the dominant ion in lipid A
isolated after growth at 25 8C [14].
Fn mutant 1, with a transposon inserted in the FTN_1403
gene, (http://www.francisella.org/) lacked the minor ion
species at m/z 1827, as compared to WT Fn spectra (compare
Figure 1A and 1B), suggesting the loss of a single hexose
moiety ( D162 m/z) from the Fn lipid A structure. This Fn
gene was shown to be a homolog of S. typhimurium pmrF
(Figure S1A and S1B) and was named Fn ﬂmF1( Francisella
lipid A modiﬁcation). Due to the presence of galactosamine
in the major lipid A structure at the 1 position (m/z 1665), we
propose that this second hexose residue is attached directly
to the glucosamine backbone at the 49 position. To determine
the identity of the unknown hexose sugar present in WT Fn,
but not ﬂmF1, lipid A samples isolated after growth at 37 8C
were hydrolyzed to obtain individual carbohydrate residues
and analyzed as the trimethylsilyl derivatives using gas
chromatography-mass spectrometry (GC-MS) analysis. GC-
MS electron-impact mass spectra indicated that the addi-
tional hexose was mannose (unpublished data).
The presence of the phosphate-free addition of mannose
found in this study was novel to Francisella lipid A biosyn-
thesis, though it had been previously described in a variety of
purple sulfur phototrophic bacteria [21–23] and the obligate
predatory bacterium Bdellovibrio [24]. The signiﬁcance of this
modiﬁcation in Fn is currently unknown, however upon
growth at low temperatures (25 8C or lower), increased levels
of mannose were observed [14]. Interestingly, the presence of
mannose was observed only in lipid A isolated from either
Type A F. tularensis subspecies tularensis (ﬁve of seven isolates)
[10] or Fn strain U112, but not Type B F. tularensis subspecies
holarctica (zero of 11 isolates), or F. tularensis subspecies
mediasiatica (zero of three isolates) after growth at 25 8C
(unpublished data).
Fn mutant 2, with a transposon inserted in the FTN_0545
gene, showed a major peak at m/z 1504, which represented the
parent tetra-acylated lipid A structure lacking the 1 position
phosphogalactosamine ( Dm/z 161) residue (Figure 1C). The
ion species at m/z 1666 represented a tetra-acylated structure
that contained mannose but lacked galactosamine (m/z 1504
ion þ 162 mass units). This gene was shown to be a second
homolog of S. typhimurium pmrF (Figure S1A and S1B) and was
named Fn ﬂmF2. Interestingly, lipid A isolated from the Type
B strain, LVS (Live Vaccine Strain), does not contain
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Author Summary
Bacterial pathogens modify outer membrane components, such as
lipid A or endotoxin, the lipid anchor of lipopolysaccharide, to
enhance the ability to colonize, spread to different tissues, and/or
avoid the host’s immune defenses. Lipopolysaccharide also plays an
essential role in maintaining membrane integrity and is a key factor
in host innate immune recognition of Gram-negative bacterial
infections. Francisella tularensis is the causative agent of the human
disease tularemia and is classified as a category A select agent.
Francisella novicida (Fn) is the murine counterpart of F. tularensis.
The structure of Francisella spp. lipid A is unique in that it is
modified by various carbohydrates that play a role in virulence and
altered endotoxicity. In our study, we identified and defined the role
of three genes involved in the carbohydrate modification of the
base Fn lipid A structure. We showed that the lack of specific
modification(s) of the Fn lipid A molecule lead to bacterial
attenuation and activation of a protective immune response against
a lethal wild-type infection. Therefore, alteration of Francisella lipid A
structure may represent a pathogenesis strategy common to the
Francisella species, and specific lipid A mutant strains may be
candidates for inclusion in future vaccine studies.galactosamine, suggesting one possible mechanism for the
avirulence/protection phenotype of this strain.
Finally, Fn mutant 3, with a transposon insertion in the
FTN_0546 gene, showed a major ion peak at m/z 1504, which
corresponded to a lipid A molecule that did not contain
either carbohydrate modiﬁcation (loss of Dm/z 161 (galactos-
amine) and 162 (mannose) residues) (Figure 1D). Therefore,
this gene functions to transfer two sugar residues to the lipid
A backbone structure. This gene was shown to be a homolog
of S. typhimurium pmrK (Figure S1A and S1C) and was named
Fn ﬂmK.
The absence of speciﬁc carbohydrate modiﬁcations was
conﬁrmed by gas chromatography/mass spectrometry analysis
for all Fn mutant strains (unpublished data). The individual
Fn lipid A biosynthetic mutants did not affect O-antigen
production. WT O-antigen laddering proﬁles, as determined
by tricine SDS-PAGE gel electrophoresis using whole cell
preparations or puriﬁed LPS, were observed for all strains
tested (unpublished data).
Attenuation of F. novicida Lipid A Mutants in Infected
Mice
Using murine models of infection (subcutaneous and
pulmonary), we determined the role of the individual lipid
A biosynthetic mutants in virulence. Initially, C57BL/6 and
BALB/c mice were infected subcutaneously to mimic zoonotic
transmission, with either WT Fn (LD100 ; 1–10 cfu) or the
three individual mutants, and their disease symptoms were
observed. The ﬂmF2 and ﬂmK mutants were attenuated in
mice, as all of the infected mice survived infection, in contrast
to those infected with WT Fn or the ﬂmF1 mutant (Figure 2A),
which died 2 d post-infection. Similar results for all strains
were observed in BALB/c mice (unpublished data).
To mimic the air-borne route of infection, C57BL/6 mice
were infected with WT Fn or the mutants using a nose-only
chamber to ensure that only an airway infection was achieved.
It was previously determined that mice infected with as few as
5 cfu/lung via exposure to aerosolized WT Fn died on day 4
post-infection (S. J. Skerrett, unpublished data). C57BL/6
mice were exposed to aerosolized ﬂmF1, ﬂmF2, or ﬂmK mutant
bacteria (resulting in depositions of 66–120 cfu/lung). Similar
to the subcutaneous infection studies, the ﬂmK mutant was
attenuated and mice infected with this mutant showed no
signs of illness and uniformly survived the infection (Figure
2B). However, mice exposed to the ﬂmF2 mutant showed mild
clinical manifestations of disease (scruffy coat, lethargy) with
a single mouse dying on day 9. In contrast to the ﬂmF2 and
ﬂmK mutants, the ﬂmF1 mutant retained its virulence and all
ﬂmF1-infected mice died at day 4, kinetics similar to infection
with WT bacteria. This ﬁnding was similar to the results
observed in mice infected via the subcutaneous route. This
avirulent phenotype for the ﬂmF2 and ﬂmK mutants was not
Figure 1. Lipid A Structures and Profiles from MALDI-TOF Mass Spectrometry Analysis of Francisella (A) WT, (B) flmF1 Mutant, (C) flmF2 Mutant, and (D)
flmK Mutant
doi:10.1371/journal.ppat.0040024.g001
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Francisella Lipid A Modificationsdue to attenuation of growth in vitro, as the mutant strains
displayed similar doubling times to WT Fn when grown in a
rich culture medium (Figure S2A). In addition, similar
numbers of bacteria were recovered from cultured alveolar
macrophages (MH-S cell line) after infection with both the
mutants and WT Fn (Figure S2B).
Bacterial Replication in Infected Mice
To determine the kinetics of bacterial replication and
spread following infection, C57BL/6 mice were infected
subcutaneously with WT or ﬂmF1, ﬂmF2, or ﬂmK mutant
bacteria (;400–500 cfu). Spleens, livers, and lungs were
harvested from infected mice at day 1, 2, 4, 7, and 14 post-
infection and plated to determine individual organ burden.
WT and ﬂmF1 bacteria were able to efﬁciently replicate in
vivo: ;10
4 and 10
8 cfu were recovered from the spleen and
liver within 1 and 2 d post-infection, respectively (Figure 3
and unpublished data). In contrast, lower numbers of ﬂmK
mutant bacteria (;10–100 cfu) were found in the spleen and
liver at 1 d post-infection. The ﬂmK mutant was completely
cleared by day 4 post-infection, as bacteria were not found in
any organ examined. The ﬂmF2 mutant initially replicated,
with bacterial deposition in the spleen increasing to ;10
4 cfu
at day 1 post-infection, but it was eventually cleared by day 14
(Figure 3). These results show that mice were able to clear the
attenuated ﬂmK and ﬂmF2 mutants but not the virulent ﬂmF1
or WT bacteria.
Similar results were observed in C57BL/6 mice infected by
aerosolization of WT or ﬂmK mutant bacteria (;100 cfu/lung).
Initially, both the WT and ﬂmK bacteria replicated in the
lungs, reaching about 3-log of the initial dose at day 1 post-
infection. However, by day 3 post-infection, higher bacterial
burdens were observed in the lungs, spleens, and livers of the
WT-infected animals as compared to those infected with the
ﬂmK mutant (Figure 4). The bacterial burden in ﬂmK-infected
mice was cleared by day 14 post-infection.
Innate Immune Response to flmK Mutant
Since both the ﬂmK and ﬂmF2m u t a n ts t r a i n sw e r e
attenuated in the murine model via both the pulmonary
and subcutaneous routes of infection, we determined the
potential role of the host innate immune system in
recognition and clearance of these mutants. To test for
enhanced recognition and/or increased pro-inﬂammatory
cytokine and chemokine production, a mouse alveolar
macrophage cell line (MH-S cells) was infected with WT or
mutant bacteria. Culture supernatants were collected at 6 and
24 h post-infection and assayed for TNF-a and MIP-2
production by ELISA. At 24 h post-infection, the ﬂmK and
ﬂmF2 mutant stimulated enhanced TNF-a (Figure 5A) and
MIP-2 (Figure 5B) production relative to WT Fn (p , 0.001).
To determine the inﬂammatory response during pulmonary
infection, polymorphonuclear leukocytes (PMN) in bron-
choalveolar lavage (BAL) ﬂuids from mice exposed to
Figure 2. Mouse Survival after F. novicida Infection
(A) C57BL/6 mice (n¼5) were injected subcutaneously with flmF1 (1,360 cfu), flmF2 (960 cfu), or flmK (1,280 cfu). Mice infected with lethal dose of WT Fn
died at day 2 post-infection (unpublished data), (B) C57BL/6 mice (n¼4) were exposed to aerosolized flmF1 (deposition¼66 cfu/lung), flmF2 (120 cfu/
lung), or flmK (71 cfu/lung). Mice infected with lethal dose of WT Fn died at day 4 post-infection (unpublished data). Representative of two independent
experiments.
doi:10.1371/journal.ppat.0040024.g002
Figure 3. Bacterial Burden in (A) Spleen, (B) Liver, and (C) Lung of Mice after Subcutaneous Infection with WT, flmF2, or flmK Mutant Bacteria
C57BL/6 mice (n¼3 each group) were injected with WT ( , 520 cfu), flmF2( 3, 465 cfu), or flmK (m, 425 cfu) mutant bacteria. Mice infected with WT Fn
were all dead by day 2 post-infection. Representative of two independent experiments.
doi:10.1371/journal.ppat.0040024.g003
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Francisella Lipid A Modificationsaerosolized WT Fn or ﬂmK mutant bacteria were enumerated.
The number of PMN in BAL ﬂuids was signiﬁcantly higher at
24 h post-inhalation of the ﬂmK mutant as compared to WT
Fn (Figure 5C).
To further dissect the role of the innate immune response
to the ﬂmK mutant, the importance of the TLR system (and/or
IL-1/IL-18) in controlling infection was tested in MyD88
knockout mice. Bone marrow–derived macrophage (BMMø)
from C57BL/6 mice secreted signiﬁcantly higher levels of IL-6
and MIP-2 in response to infection by the ﬂmK mutant than
in response to WT Fn (Figure 6A and 6B, MOI ¼ 100, p ,
0.001). Signiﬁcant differences in the production of IL-6 (p ,
0.02) and MIP-2 (p , 0.05) were also observed at MOI 10
(unpublished data). Levels of lactate dehydrogenase (LDH) in
supernatants, harvested at 6 and 24 h after infection, from
C57BL/6 BMMø infected with either strain of bacteria, at both
MOI 10 and MOI 100 were similar (unpublished data). These
results suggest that decreased production of both IL-6 and
MIP-2 for WT-infected cells, as compared to the ﬂmK mutant
was not a result of cell death. Similar results were found in
BMMø derived from TLR4
 /  and TLR2/4
 /  mice. However,
IL-6 and MIP-2 were undetectable in MyD88
 / -derived
BMMø cultures stimulated with either strain of Fn, demon-
strating the requirement for MyD88 signaling in the innate
immune response to ﬂmK infection.
The importance of the MyD88 signaling pathway in the
response to ﬂmK mutant infection was further evaluated in
vivo. MyD88
 /  mice and WT mice were exposed to
aerosolized ﬂmK bacteria (;100 cfu) and disease development
was monitored. MyD88
 /  mice were highly susceptible to
ﬂmK mutant infection and all died by day 6 post-infection,
whereas all WT mice infected with ﬂmK bacteria showed no
signs of disease and survived for at least 30 d post-infection
(Figure 7A). Similar results (Figure 7B) were observed after
subcutaneous infection of MyD88
 /  mice (;500 cfu of ﬂmK
mutant). Interestingly, all ﬂmK-infected MyD88
 /  mice died
by day 9 post-infection, a time point greatly delayed relative
to WT mice infected with WT Fn.
One arm of the innate immune system is the eradication of
colonizing microorganisms by nonspeciﬁc killing mecha-
nisms. Antimicrobial peptides target the bacterial membrane
via electrostatic interactions, leading to the disruption of the
outer membrane. Therefore, we determined the susceptibility
of the various lipid A mutants to polymyxin B, a cyclic
cationic antimicrobial peptide, using a disc diffusion assay.
Both the WT and the lipid A modiﬁcation gene mutant
bacteria (ﬂmF1, ﬂmF2, and ﬂmK) were shown to be highly
resistant to killing, whereas as a control a Fn lipid A
biosynthetic 49 position phosphatase-null mutant (lpxF) was
susceptible, as previously shown [18] (Figure S3).
Figure 4. Bacterial Burden in (A) Lung, (B) Spleen, and (C) Liver after Exposure of C57BL/6 Mice to Aerosolized WT Fn
( , deposition ¼ 100 6 29 cfu/lung) or flmK mutant (m, deposition ¼ 146 6 62 cfu/lung)
Mice infected with WT Fn were all dead by day 4 post-infection. Representative of two independent experiments.
doi:10.1371/journal.ppat.0040024.g004
Figure 5. Pro-Inflammatory Cytokine Production by Infected Murine Macrophages
Mean 6 SEM of (A) TNF-a and (B) MIP-2 concentration from MH-S culture supernatants after infection with WT, flmF2, or flmK mutant bacteria (MOI
;100) at 6 h (open bars) and 24 h (filled bars) post-infection. Representative of two independent experiments. Differences were not significant at 6 h
post-infection.
(C) PMN enumerations in BAL fluid of mice infected with aerosolized WT (open bar) or flmK mutant (filled bar) bacteria. Representative of two
independent experiments. There was no significant difference at 4 and 72 h post-infection.
doi:10.1371/journal.ppat.0040024.g005
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To determine if mice that survived initial subcutaneous
infection were protected from subsequent challenge with WT
Fn, the surviving ﬂmF2 and ﬂmK mice (;30–35 d post initial
infection) were challenged with a lethal dose of WT Fn (660
cfu). Mice that were initially infected with the ﬂmK mutant
acquired protective immunity (Figure 8A), as only a single
mouse (n¼5) died on day 5 post challenge. As a control, naı ¨ve
C57BL/6 mice were infected with WT Fn at the same dose and
all died at day 2 post-infection (unpublished data). In
contrast, mice initially infected with the ﬂmF2 mutant were
not protected against WT Fn infection, as all mice died by day
5 post WT challenge. Similar results were observed for both
mutants in BALB/c mice that were initially infected subcuta-
neously (unpublished data).
Protection studies were also performed using mice that
were initially infected by aerosolization. Using a lethal dose
(25 cfu) of WT Fn for challenge, complete protection was
obtained when mice were initially infected with either the
ﬂmF2o rﬂmK mutants (Figure 8B). As a control, naı ¨ve C57BL/6
mice were infected with WT Fn at the same dose and all died
at approximately day 4 post-infection. These results show that
initial infection/immunization using the ﬂmK mutant pro-
vided nearly complete protection against WT Fn challenge
via both pulmonary and subcutaneous routes of infection.
Interestingly, the ﬂmF2 mutant provided protection only
through aerosolization but not through subcutaneous in-
fection, suggesting that the route of initial infection may be
important in the generation of a protective response.
Discussion
Lipid A of Francisella is different from those of classical
enteric bacteria in terms of its structure and biological
activities. Francisella lipid A has tetra-acyl chains of 16–18
carbons in length and the phosphate moiety at the 49 position
is removed by the LpxF phosphatase enzyme. This molecule
can be further modiﬁed by the addition of galactosamine
Figure 6. Cytokine and Chemokine Production by BMMø
Mean 6 SEM of (A) IL-6 and (B) MIP-2 concentration in culture supernatants at 24 h after infection of BMMø from C57BL/6 (open bars) or MyD88
 / 
(filled bars) mice with WT or flmK mutant bacteria (MOI 100). Significant differences were observed between C57BL/6 and MyD88
 /  mice.
doi:10.1371/journal.ppat.0040024.g006
Figure 7. MyD88
 /  Mice Are Susceptible to flmK Mutant Infection
MyD88
 /  ( ) or C57BL/6 ( ) mice were (A) exposed to aerosolized (30 cfu) or (B) infected subcutaneously (508 cfu) with flmK mutant bacteria.
Representative of two independent experiments.
doi:10.1371/journal.ppat.0040024.g007
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Francisella Lipid A Modificationsonto the 1-phosphate moiety. Another unique modiﬁcation is
the presence of glucose at the 69 position to free lipid A [25],
which has a similar molecular mass as Fn lipid A that contains
the mannose modiﬁcation described above.
In this study, three genes required for the carbohydrate
modiﬁcation of Fn lipid A were identiﬁed. Two of the genes,
FTN_1403 (ﬂmF1) and FTN_0545 (ﬂmF2), functioned sim-
ilarly to the S. typhimurium PmrF enzyme and are proposed to
be involved in the transfer of mannose or galactosamine,
respectively, to undecaprenyl phosphate, a polyisoprenoid
carrier lipid required for the transport of water soluble
precursors across a lipid membrane (Figure 1A). Inactivation
of the third gene, FTN_0546 (ﬂmK), recently described by
Wang et al. [18] for the addition of only galactosamine,
resulted in the loss of both galactosamine and mannose
modiﬁcations, suggesting that this gene functions to transfer
the individual carbohydrate moieties from undecaprenyl
phosphate to lipid A, similar to the function of PmrK in S.
typhimurium. All three genes are highly homologous among
the sequenced Francisella subspecies genomes (Type A –
Schu4, WY96–3418; Type B – OSU18, LVS; Fn – U112) with
overall amino acid sequence similarity of 98.3%–99.7%,
suggesting a conserved function for these enzymes (Figure
S1A).
Mutants in ﬂmF2 and ﬂmK were attenuated in mice by both
pulmonary and subcutaneous routes of infection. Both
mutant strains provided protection against a lethal WT
Francisella infection and induced protective immunity in mice
vaccinated via the pulmonary route of infection. Interest-
ingly, only the ﬂmK mutant provided protective immunity
when initial infection was performed via subcutaneous
injection.
As the ﬂmK mutant showed the most promising outcome in
terms of attenuation and induction of protective immunity,
further work was focused on this mutant. We hypothesized
that the ﬂmK mutant would stimulate an increased immune
response, particularly via the innate arm of host immunity.
This hypothesis was supported by the ﬁndings that ﬂmK
mutant infection resulted in enhanced induction of pro-
inﬂammatory cytokine and chemokine production in a
mouse alveolar macrophage cell line and in BMMø in vitro
and enhanced elicitation of neutrophils to the lungs in vivo,
in comparison with WT Fn infection. We also showed that
MyD88-mediated signaling was involved in the innate
immune response stimulated by the ﬂmK mutant, as the
augmented cytokine response of BMMø to this mutant
required MyD88, and infection with the ﬂmK mutant was
lethal in mice lacking MyD88 (albeit with delayed kinetics in
comparison to the lethality of WT Fn infection in C57BL/6
mice). These observations suggested that the ﬂmK mutant
might be more readily recognized by TLRs than is WT type
Fn. Indeed, we found that the augmented cytokine response
of BMMø to the ﬂmK mutant was partially dependent on
TLR2 and TLR4. However, whereas MyD88-deﬁcient mice
succumbed to infection with the ﬂmK mutant (Figure 7), no
mortality was observed after subcutaneous ﬂmK infection of
mice lacking TLR4 or both TLR2 and TLR4 (unpublished
data). Thus, MyD88-dependent responses that are independ-
ent of TLR2 and TLR4 appear to be essential to the
protective response elicited by the ﬂmK mutant. The
signiﬁcance of the MyD88 signaling pathway has been shown
in a model of LVS infection, where susceptibility of MyD88
knock out mice to Francisella infection was enhanced, even at
a very low dose of bacteria (10
6-fold less than LD50) [26].
The importance of the innate immune response in control
of Fn infection has been previously demonstrated. Recently,
Wang et al. showed that a Fn mutant with a defect in LpxF, an
enzyme that removes the phosphate moiety from the 49
position of the lipid A molecule, was highly attenuated in vivo
(intradermal injection into mouse footpad) [27], though it
displayed a signiﬁcant defect in growth in vitro in rich culture
medium (TSBC). This mutant strain elicited increased
cytokine responses and inﬂammatory cell recruitment as
compared to WT Fn after intraperitoneal injection of mice.
The LpxF-null strain was also more sensitive to the cyclic
cationic antimicrobial peptide polymyxin B.
The ability of the ﬂmK mutant to activate the innate
immune response may be responsible for the rapid clearance
of the bacteria from mice before causing disease symptoms.
Furthermore, this recognition may also lead to the potent
induction of adaptive immune responses that provide
protection against WT Francisella challenge. Due to the close
genetic relatedness and similarity in lipid A structure among
all four subspecies of Francisella [10], it is likely that
inactivation of the ﬂmK gene in other subspecies would also
result in bacterial attenuation and activation of adaptive
immunity. Protection against WT bacterial challenge was
obtained after initial priming with the mutants, especially
Figure 8. Mouse Survival after a Lethal WT F. novicida Challenge
(A) C57BL/6 mice that survived primary flmF2( 3)o rflmK (n) subcutaneous infection were challenged with WT Fn (660 cfu) via the subcutaneous route.
(B) C57BL/6 mice that survived primary flmF2( 3)o rflmK (n) pulmonary infection were challenged via the pulmonary route with WT Fn (25 cfu).
Representative of two independent experiments.
doi:10.1371/journal.ppat.0040024.g008
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induction of a pro-inﬂammatory response via the MyD88-
mediated signaling pathway were shown to be essential for
clearance of ﬂmK and possibly for protection. These results
suggest that carbohydrate modiﬁcations of lipid A play an
important role in bacterial virulence and protective immun-
ity and may aid in the development of an effective Francisella
vaccine in the future.
Materials and Methods
Bacterial strains. WT Fn U112 was obtained from Francis Nano
(University of Victoria, Victoria, Canada) and the U112 lpxF mutant
(XWK4) was obtained from Christian Raetz (Duke University,
Durham, North Carolina). A mutant library (http://www.francisella.
org/) was generated by transposon random mutagenesis of Fn strain
U112 as part of a screen for essential genes in Fn [28]. Bacteria were
cultured overnight in tryptic soy broth medium supplemented with
0.1% cysteine (TSBC) at 37 8C [10].
Mouse strains. C57BL/6 and BALB/c mice (female, 6–8 wk old) were
purchased from Jackson Laboratories. Mice were maintained under
speciﬁcpathogen-freeconditions. Mice were 6–12wkof age at the time
of experimental infection. All animal experiments were approved by
the Institutional Animal Care and Use Committee of the University of
Washington (Seattle, Washington). TLR4
 /  and TLR2/4
 /  mice were
kindly provided by Dr. C. B. Wilson (University of Washington, Seattle,
Washington). MyD88
 /  mice were kindly provided by Dr. S. Akira
(Osaka, Japan) [29]. They were backcrossed to C57BL/6 mice for eight
generations and then intercrossed to generate MyD88
 /  mice [30].
Screening for mutants with a defect in lipid A synthesis and
modiﬁcation. Lipid A from individual transposon mutants was
extracted using an ammonium hydroxide/isobutyric acid method
[31] and subjected to negative ion matrix-assisted laser desorption
ionization time-of-ﬂight (MALDI-TOF) mass spectrometry analysis
[10]. Brieﬂy, pellets from 5 ml of O/N cultures of individual Fn mutants
were resuspended in 400 ll isobutyric acid/1M ammonium hydroxide
(5:3, v:v) and incubated at 100 8C for 2 h, with occasional vortexing.
Samples werecooled on ice for 5 minand centrifuged (2,000 x g) for 15
min at RT. The resulting supernatant was transferred to a new tube,
diluted with an equal volume of water, and lyophilized. The dried lipid
A was resuspended in 400 ll methanol and centrifuged as above, twice.
The lipid A pellet was solubilized in 200 ll chloroform/methanol/water
(3:1.5:0.25, v:v:v) and spotted (1 ll) directly onto the MALDI sample
plate, followed by 1 ll of 20 mg/ml 5-chloro-2-mercapto-benzothiazole
(CMBT) MALDI matrix dissolved in chloroform/methanol (1:1, v/v). All
MALDI-TOF experiments were performed using a Bruker Autoﬂex II
MALDI-TOF mass spectrometer (Bruker Daltonics, Incorporated).
Each spectrum was an average of 300 shots. A tuning mix (Agilent) was
used to calibrate the MALDI-TOF. Spectra obtained from the
individual transposon mutants were compared with that of WT Fn.
MALDI-TOF results were conﬁrmed by large phenol preparations of
LPS/lipid A for speciﬁc mutant strains [10].
In vitro replication and stimulation of mouse alveolar macrophage
cell line. The MH-S mouse alveolar macrophage cell line (ATCC) was
maintained at 37 8Cw i t h5 %C O 2 in RPMI 1640 medium
supplemented with 2 mM L-Glutamine (Sigma), 10mM HEPES
(Invitrogen), 10% fetal calf serum (Hyclone), 100 units/ml penicillin,
and 100 lg/ml streptomycin (Sigma). For the intracellular replication
and stimulation assays, MH-S cells were washed four times with media
without antibiotics and plated in 24-well plates precoated with 0.01%
poly-L-lysine (Sigma) at a cell density of 10
5 cells/well overnight, as
previously described [10]. Cells were infected the next day with WT or
mutant bacteria at the indicated multiplicity of infection. For
intracellular replication experiments, cells were washed with 1x
phosphate-buffered saline (PBS, Sigma) four times after 2 h of
infection. To harvest bacteria, saponin (0.2% saponin/PBS) was added
to each well to a ﬁnal concentration of 0.1% (w/v). Bacteria were
harvested at 24 and 48 h after infection. Bacterial counts were
performed by plating serial dilutions of bacteria onto TSBC plates
and incubating at 37 8C for 48 h. For stimulation assays, MH-S cells
were not washed after infection and culture supernatants were
collected from plates 6 and 24 h after infection [10]. TNF-a and MIP-2
were measured in these supernatants using ELISA Duoset kits
according to manufacturer’s instructions (R&D Systems).
Virulence and protection studies. For subcutaneous infection, mice
were injected with WT Fn or mutant bacteria into the subcutaneous
tissue overlying the abdomen. For pulmonary infection, mice were
exposed to aerosolized bacteria using a nose-only inhalation system,
as previously described [10]. Bacterial deposition in the lungs in each
experiment was determined by quantitative culture of homogenized
lung tissue harvested from mice killed immediately after exposure.
Mice were observed daily for clinical manifestations of disease. To
study development of protective immunity, mice previously infected
with mutants were challenged with WT bacteria at 30–35 d post-
initial infection and survival of the mice was recorded.
Bacterial burden in mouse organs. For subcutaneous infection
experiments, mice were infected at the indicated dose. At days 1, 2, 4,
7, 10, and 14 post-infection, mice (n¼3 each group) were euthanized
by CO2 narcosis. Spleen, left lobe of liver, and left lung were
harvested and homogenized in 0.5 ml of PBS containing 0.1%
saponin. Bacterial suspensions were serially diluted and plated onto
TSBC agar plates for quantitative culture. Colonies were counted
after incubation at 37 8C for 48 h.
For pulmonary infection experiments, mice were exposed to
aerosolized bacteria. Immediately and at 1, 3, 7, and 14 d post-
infection, mice were euthanized with an intraperitoneal injection of
pentobarbital then exsanguinated by cardiac puncture. Initial
bacterial deposition was determined by quantitative culture of
homogenized lung tissue harvested from four mice immediately after
infection. At the indicated time points, the left lungs, livers, and
spleens from four mice in each group were homogenized in 1 ml PBS
for quantitative culture.
Bronchoalveolar lavage cell counts. At 4, 24, and 48 h after
exposure to aerosolized bacteria, mice were euthanized with an
intraperitoneal injection of pentobarbital then exsanguinated by
cardiac puncture. The trachea of each mouse was cannulated, and the
right lung lavaged with 4 0.5-ml aliquots of 0.9% NaCl supplemented
with 0.6 mM EDTA [32]. Cell counts in bronchoalveolar lavage (BAL)
specimens were measured in a hemocytometer. Differentials were
determined from examination of cytocentrifuge slides (Thermo
Shandon) that were stained with a modiﬁed Wright-Giemsa techni-
que (Diff-Quik; Dade Behring).
Bone marrow–derived macrophages. Bone marrow cells were har-
vested from both femurs and tibias of wild-type C57BL/6, TLR4
 / ,
TLR2/4
 / , and MyD88
 /  mice. Bone marrow cells were washed and
resuspended in RPMI 1640 medium supplemented with 10% FCS, 100
units/ml penicillin, 100 lg/ml streptomycin, and 20% L929-condi-
tioned medium. Cells were grown on bacterial culture plates. Culture
medium was added on day 2 and cells were collected on day 5. BMMø
were lifted from plates, washed with 1xPBS, resuspended in anti-
biotic-free medium, and plated into 24-well tissue culture plates.
BMMø were infected with bacteria at MOI 1, 10, and 100 and culture
supernatants were collected at 6 and 24 h after infection. IL-6 and
MIP-2 were assayed using ELISA Duoset kits (R&D Systems). E. coli
O111:B4 LPS (1000 ng/ml) was used in these studies as a positive
control for TLR4/MyD88 activation.
Data analysis. Data are expressed as means 6 SE. One-way analysis
of variance with Tukey’s post hoc test or Student t-test were used for
statistical analysis [32]. A p-value of ,0.05 was considered signiﬁcant.
Supporting Information
Figure S1. Phylogenetic Relatedness of PmrF and PmrK Enzymes
among Different Gram-Negative Bacteria
(A) Percentage of amino acid homology of FlmF and FlmK proteins.
Phylogenetic trees of (B) FlmF and (C) FlmK proteins from Francisella
tularensis subspecies novicida (U112), tularensis (Schu4), and holarctica
(LVS), Salmonella typhimurium (LT2), Escherichia coli (O157:H7), Yersinia
pestis (CO92), and Burkholderia pseudomallei (K96243). Data were
analyzed using Geneious software (http://www.geneious.com/).
FTN1403 (U112 FlmF1), FTN0545 (U112 FlmF2), FTN0546
(U112FlmK), FTT1433 (Schu4 FlmF1), FTT0454 (Schu4 FlmF2),
FTT0455 (Schu4 FlmK), FTL0625 (LVS FlmF1), FTL1611 (LVS
FlmF2), FTL1609 (LVS FlmK), STM2298 (LT2 PmrF), STM2301 (LT2
PmrK), YPO2421 (CO92 PmrF), YPO2418 (CO92 PmrK), BPSL1471
(K96243 PmrF), BPLS1474 (K96243 PmrK), ECs3142 (O157:H7 PmrF),
and ECs3145 (O157:H7 PmrK).
Found at doi:10.1371/journal.ppat.0040024.sg001 (159 KB TIF).
Figure S2. Intact In Vitro and Intracellular Replication of Fn Lipid A
Mutants
Similar growth rate of WT and mutant Francisella novicida in (A) the
rich culture medium TSBC at 37 8C and (B) in the MH-S cell line. For
the in vitro growth experiment, overnight cultures of WT, ﬂmF1,
ﬂmF2, and ﬂmK mutant bacteria were 1:100 back diluted into TSBC
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Francisella Lipid A Modificationsand grown at 37 8C. At the indicated time points, 1 ml of culture was
sampled for OD600 measurement.
Found at doi:10.1371/journal.ppat.0040024.sg002 (415 KB TIF).
Figure S3. No Hypersensitivity to Antimicrobial Peptide of Fn Lipid
A Mutants
Disc diffusion assay for sensitivity of WT and mutant Francisella
novicida to antimicrobial peptide (polymyxin B) and kanamycin. Log-
phase cultures of WT, ﬂmF1, ﬂmF2, and ﬂmK mutant bacteria were
plated onto TSBC plates. Polymyxin B (20 lg) or kanamycin (20 lg)
were spotted onto blank paper discs (6 mm in diameter) and placed
onto the plates. Plates were incubated at 37 8C for 24–48 h before
reading the diameter of the clearing zone (clearing zone marked by
black rings). Similar to WT Fn, ﬂmF1, ﬂmF2, and ﬂmK mutant bacteria
were not hypersensitive to polymyxin B.
Found at doi:10.1371/journal.ppat.0040024.sg003 (2.8 MB TIF).
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